AKT (phospho-T450) polyclonal antibody

AKT, also known as protein kinase B (PKB), is a 57 kDa serine/threonine protein kinase. There are three mammalian isoforms of Akt: AKT1 (PKB alpha), AKT2 (PKB beta) and AKT3 (PKB gamma) with AKT2 and AKT3 being approximately 82% identical with the AKT1 isoform. Each isoform has a pleckstrin homology (PH) domain, a kinase domain and a carboxy terminal regulatory domain. AKT was originally cloned from the retrovirus AKT8, and is a key regulator of many signal transduction pathways. Its tight control over cell proliferation and cell viability are manifold; overexpression or inappropriate activation of AKT has been seen in many types of cancer.

RAC-alpha serine/threonine-protein kinase; Protein kinase B; PKB; Protein kinase B alpha; PKB alpha; Proto-oncogene c-Akt; RAC-PK-alpha; AKT1; PKB; RAC; PKBα; RAC-beta serine/threonine-protein kinase; Protein kinase Akt-2; Protein kinase B beta; PKB beta; RAC-PK-beta; AKT2; PKBβ; RAC-gamma serine/threonine-protein kinase; Protein kinase Akt-3; Protein kinase B gamma; PKB gamma; RAC-PK-gamma; STK-2; AKT3; PKBG; PKBγ

Phosphoinosotode Signaling, PI3K AKT signaling, Protein Kinase C Signaling, Immune Cell Signaling, Warburg Effect, Translational Contral elF4 and p70 S6 Kinase, Regulation of Microtubule Dynamics, T cell receptor signaling, Inhibition of Apoptosis, Insulin &Glucose Signaling, Cell Cycle Control G1 S Checkpoint, Adherens Junction signaling, Mitochondrial Control of Apoptosis, MTOR signaling, ErbB HER Signaling

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

P-AKT (T450) polyclonal antibody detects endogenous levels of AKT1 only when phosphorylated at Thr450. This antibody also recognizes AKT2 and AKT3 when phosphorylated at the corresponding residues.

Western blot (WB) analysis of AKT (phospho-T450) polyclonal antibody at 1:500 dilution Lane1:L02 whole cell lysate Lane2:L02 treated with EGF (0.1ng/ml,5min) whole cell lysate Lane3:L02 treated with EGF (0.1ng/ml,10min) whole cell lysate Lane4:L02 treated with EGF (0.1ng/ml,15min) whole cell lysate